Michel Arock

This paper identifies PDE3A-SLFN12 molecular glues as a novel therapeutic target for KIT D816V-driven mast cell malignancies, showing their efficacy in killing multiple KIT D816V cell types and synergy with tyrosine kinase inhibitors.

This study identifies AXL as a driver of mast cell survival and TKI resistance in mastocytosis and shows that dual KIT/AXL inhibition restores TKI sensitivity.

This study identifies KIRA6 as a dual inhibitor of LYN and FYN that suppresses IgE-mediated mast cell activation and inflammation.